GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Operating Margin %

Baudax Bio (Baudax Bio) Operating Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Baudax Bio's Operating Income for the three months ended in Sep. 2023 was $-5.54 Mil. Baudax Bio's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Baudax Bio's Operating Margin % for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Baudax Bio's Operating Margin % or its related term are showing as below:

BXRXQ' s Operating Margin % Range Over the Past 10 Years
Min: -11319.88   Med: -4849.63   Max: -2759.89
Current: -2759.89


BXRXQ's Operating Margin % is ranked worse than
83.04% of 1026 companies
in the Biotechnology industry
Industry Median: -175.525 vs BXRXQ: -2759.89

Baudax Bio's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Baudax Bio's Operating Income for the three months ended in Sep. 2023 was $-5.54 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-35.02 Mil.


Baudax Bio Operating Margin % Historical Data

The historical data trend for Baudax Bio's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Operating Margin % Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial - - -11,319.88 -4,849.63 -2,816.63

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1,636.09 - - -

Competitive Comparison of Baudax Bio's Operating Margin %

For the Biotechnology subindustry, Baudax Bio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Operating Margin % falls into.



Baudax Bio Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Baudax Bio's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-35.743 / 1.269
=-2,816.63 %

Baudax Bio's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-5.54 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baudax Bio  (OTCPK:BXRXQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Baudax Bio Operating Margin % Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341

Baudax Bio (Baudax Bio) Headlines